Poxel has commenced its TIMES 2 and TIMES 3 trials in Japan, examining the use of Imeglimin for the treatment of type 2 diabetes.

Both studies are part of the Trials of IMeglimin for Efficacy and Safety (TIMES) programme, which includes three studies involving around 1,100 patients.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The programme has been conducted under a joint development effort between Poxel and Sumitomo Dainippon Pharma.

TIMES 2 is a Phase III, 52-week study designed to examine the long-term safety and efficacy of Imeglimin in Japanese patients with type 2 diabetes.

“Our near-term focus in Japan is the successful execution of TIMES.”

In the trial, Imeglimin will be administered orally either as a monotherapy or combination therapy. In the latter instance it will be given with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor, biguanide, sulphonylurea and GLP1 receptor agonist.

TIMES 3 is a Phase III, 16-week, placebo-controlled trial.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

It features a 36-week open-label extension period to analyse the efficacy and safety of Imeglimin in combination with insulin in Japanese patients with type 2 diabetes and inadequate glycemic control on insulin therapy.

Poxel CEO Thomas Kuhn said: “Over the last few months, we have made significant progress advancing the TIMES programme for Imeglimin in Japan with the initiation of all three pivotal Phase III trials.

“We are on track for the Phase III data readout in 2019.

“Our near-term focus in Japan is the successful execution of TIMES, and to this end, we are working closely with our colleagues at Sumitomo Dainippon Pharma to support the Japanese New Drug Application submission anticipated in 2020.”

Imeglimin simultaneously targets the three key organs that help treat type 2 diabetes; the liver, muscles and pancreas. Such a mechanism has been observed in clinical studies to have glucose-lowering benefits.

Japan is the second largest single market for type 2 diabetes outside of the U.S. and is expected to grow to approximately $6 billion in 2021.

 

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact